Screener
Eligibility screening
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
3 US sites in MD, OH, TX
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.
Screener
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
3 US sites in MD, OH, TX
Before we begin
Your answer affects how the questions are phrased.